论文部分内容阅读
目的研究乳腺癌患者ST13、Hsp70、pS2、雌激素受体(ER)和孕激素受体(PR)表达及其与生存关系。方法选择1993至1994年间有完整随访资料和蜡块的乳腺癌患者45例,以免疫组织化学法检测ER、PR、pS2、Hsp70和ST13在乳腺癌组织中的表达及相关性分析;并进行KaplanMeier生存率分析和COX生存分析。结果(1)本组乳腺癌组织中ER、pS2、PR、ST13和Hsp70表达的阳性率依次分别为77.8%、68.9%、66.7%、64.4%和62.2%。其中ST13分别与ER、PR和pS2三者呈显著正相关性(分别为P<0.01、P<0.05和P<0.05)。而ER与PR也呈非常显著的正相关性(P<0.01)。(2)KaplanMeier生存率曲线及LogRank显著性检验发现,仅ST13和Hsp70阳性者明显提高乳腺癌患者的5年生存率(P<0.05)。COX生存分析也发现ST13和Hsp70阳性提高乳腺癌患者5年生存(P<0.05)。结论(1)ER、PR、pS2、ST13和Hsp70在乳腺癌组织中均高表达,其中ER与PR及ST13与ER、PR和pS2呈非常显著的正相关性。(2)KaplanMeier生存率分析和COX生存分析均提示ST13和Hsp70阳性者明显提高乳腺癌患者的5年生存率(P<0.05)。
Objective To investigate the expression of ST13, Hsp70, pS2, estrogen receptor (ER) and progesterone receptor (PR) in breast cancer and their relationship with survival. Methods Forty-five patients with breast cancer who had complete follow-up data and wax blocks from 1993 to 1994 were recruited. The expression and correlation of ER, PR, pS2, Hsp70 and ST13 in breast cancer tissues were detected by immunohistochemistry. The Kaplan Meier Survival analysis and COX survival analysis. Results (1) The positive rates of ER, pS2, PR, ST13 and Hsp70 in breast cancer tissues were 77.8%, 68.9%, 66.7%, 64.4% and 62.2% respectively. There was a significant positive correlation between ST13 and ER, PR and pS2 (P <0.01, P <0.05 and P <0.05, respectively). ER and PR also showed a very significant positive correlation (P <0.01). (2) KaplanMeier survival curve and LogRank significance test found that only ST13 and Hsp70 positive patients significantly increased 5-year survival rate of breast cancer patients (P <0.05). COX survival analysis also found that ST13 and Hsp70 positive increased 5-year survival in breast cancer patients (P <0.05). Conclusions (1) The expression of ER, PR, pS2, ST13 and Hsp70 are all highly expressed in breast cancer tissues. There is a significant positive correlation between ER, PR, ST13 and ER, PR and pS2. (2) KaplanMeier survival analysis and COX survival analysis both showed that the ST13 and Hsp70 positive patients significantly improved the 5-year survival rate of breast cancer patients (P <0.05).